-
Although cigarette smoking is the primary risk factor for lung cancer (LCA), with similar amounts of smoking exposure some groups demonstrate greater incidence of LCA than others.
-
The fda has approved the first non-injectable insulin for the treatment of type 1 and type 2 diabetes called Exubera®.
-
The CDC recommends that QuantiFERON®-TB Gold (QFT-G) may be used in all circumstances in which the TST is currently used, including contact investigations, evaluation of recent immigrants, and sequential-testing surveillance programs for infection control (eg, those for health-care workers).
-
Mean oral temperatures decline with age, ranging from 97.3°F at 6 am to 97.8°F at 10 pm in persons older than 65 years. The majority of both nursing home and community elderly have normal mean temperatures below 98.6°F.
-
Add vardenafil to the list of phosphodiesterase type 5 inhibitors with promise in the treatment of Raynaud disease.
-
Cardiovascular disease affects 25% of the U.S. population. It is responsible for more than 1 million deaths each year, which makes it the number one killer in the United States. Fifty percent of men and 64% of women who suffer from sudden cardiac death have no previous history or symptoms of heart disease.
-
Can Calcium and Vitamin D Prevent Hip Fractures?; Treatment of Benign Prostatic Hyperplasia; Treatment of Osteoarthritis of the Knee; Refractory Asthma and TNFConnection?; FDA Actions
-
-
Erectile Dysfunction and Subsequent Cardiovascular Disease; Oseltamivir Resistance during Influenza A Infection; Dietary Intake of Antioxidants and AMD
-
The FDA has approved a new drug for the treatment of gastrointestinal stromal tumor and metastatic renal cell cancer. Sunitinib is an orally active, highly selective, multi-targeted tyrosine kinase inhibitor. The drug was given a priority review and was approved in less than 6 months. Sunitinib is marketed by Pfizer as Sutent®.